Alan P. Z. Skarbnik, MD, highlights the approval of tazemetostat in relapsed/refractory follicular lymphoma.
Alan P. Z. Skarbnik, MD, a hematologist/oncologist with Novant Health, highlights the approval of tazemetostat (Tazverik) in relapsed/refractory follicular lymphoma.
Tazemetostat is a selective EZH2 inhibitor that was previously approved for locally advanced or metastatic epithelial sarcoma, says Skarbnik.
On June 18, 2020, the FDA granted an accelerated approval to tazemetostat for patients with EZH2-positive relapsed/refractory follicular lymphoma who have received at least 2 prior lines of therapy, says Skarbnik.
The approval was based on results from 2 cohorts of a phase 2 trial (NCT01897571) that included patients with EZH2-mutated follicular lymphoma and EZH2 wild-type follicular lymphoma, Skarbnik explains. To date, there are no phase 3 studies with tazemetostat to compare historical standards with.
Notably, the EZH2 molecule can be mutated or upregulated in a small number of cases; however, there is currently no available assay that can be used to evaluate EZH2 upregulation, Skarbnik concludes.